Ipca Laboratories gets healthier after robust Q3 results

Ipca Laboratories gained 1.93% to Rs 567.05 at 12:51 IST on BSE after net profit jumped 155% to Rs 105.58 crore on 15% rise in total income to Rs 870.18 crore in Q3 December 2017 over Q3 December 2016.

Earnings before interest, tax, depreciation and amortization (EBITDA) margin rose to 19.79% in Q3 December 2017 compared with 14.79% in Q3 December 2016. The result was announced during market hours today, 7 February 2018.

Meanwhile, the S&P BSE Sensex was down 46.75 points, or 0.14% to 34,149.19. The S&P BSE Mid-Cap index was up 129.72 points, or 0.8% to 16,410.81, outperforming the Sensex.

On the BSE, 6,878 shares were traded in the counter so far, compared with average daily volumes of 29,000 shares in the past two weeks. The stock had hit a high of Rs 580 and a low of Rs 560 so far during the day. The stock had hit a 52-week high of Rs 656 on 5 April 2017. The stock had hit a 52-week low of Rs 400 on 11 August 2017.

The stock had underperformed the market over the past one month till 6 February 2018, declining 4.56% compared with 0.12% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 5.78% as against Sensex's 1.38% rise. The scrip had, however, underperformed the market in past one year, advancing 5.64% as against Sensex's 20.24% rise.

The mid-cap company has equity capital of Rs 25.24 crore. Face value per share is Rs 2.

IPCA Laboratories is a fully-integrated pharmaceutical company.

Powered by Capital Market - Live News